Exclusive Summary

• **Clear Strategic Positioning**: UB522 is an investigational immune modulator aimed at achieving a "Functional Cure" for Chronic Hepatitis B (CHB), addressing the high unmet need where current standard of care only suppresses the virus.
• **Proprietary Platform Advantage**: Leveraging the A-proX™ AI-based Prodrug Platform, UB522 is designed for targeted liver delivery, potentially enhancing local immune response while minimizing systemic toxicity common in immune modulators.
• **Ideal Combination Partner**: As a potential cornerstone for combination therapies, UB522 complements direct-acting antivirals, offering significant value to overseas pharma companies looking to strengthen their liver disease portfolios with early-stage, high-potential assets.